JP2024045121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024045121A5 JP2024045121A5 JP2023218600A JP2023218600A JP2024045121A5 JP 2024045121 A5 JP2024045121 A5 JP 2024045121A5 JP 2023218600 A JP2023218600 A JP 2023218600A JP 2023218600 A JP2023218600 A JP 2023218600A JP 2024045121 A5 JP2024045121 A5 JP 2024045121A5
- Authority
- JP
- Japan
- Prior art keywords
- administered subcutaneously
- formulation
- isolated antibody
- use according
- milligrams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 4
- 206010021263 IgA nephropathy Diseases 0.000 claims 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 3
- 210000003743 erythrocyte Anatomy 0.000 claims 3
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649489P | 2018-03-28 | 2018-03-28 | |
| US62/649,489 | 2018-03-28 | ||
| JP2020551797A JP7526099B2 (ja) | 2018-03-28 | 2019-03-27 | 抗ｃｄ３８抗体の皮下投薬 |
| PCT/IB2019/000314 WO2019186273A1 (en) | 2018-03-28 | 2019-03-27 | Subcutaneous dosing of anti-cd38 antibodies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551797A Division JP7526099B2 (ja) | 2018-03-28 | 2019-03-27 | 抗ｃｄ３８抗体の皮下投薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024045121A JP2024045121A (ja) | 2024-04-02 |
| JP2024045121A5 true JP2024045121A5 (enExample) | 2024-11-15 |
Family
ID=66647425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551797A Active JP7526099B2 (ja) | 2018-03-28 | 2019-03-27 | 抗ｃｄ３８抗体の皮下投薬 |
| JP2023218600A Pending JP2024045121A (ja) | 2018-03-28 | 2023-12-25 | 抗ｃｄ３８抗体の皮下投薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551797A Active JP7526099B2 (ja) | 2018-03-28 | 2019-03-27 | 抗ｃｄ３８抗体の皮下投薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210047427A1 (enExample) |
| EP (1) | EP3774915A1 (enExample) |
| JP (2) | JP7526099B2 (enExample) |
| KR (2) | KR20210002499A (enExample) |
| CN (1) | CN112154156A (enExample) |
| AU (2) | AU2019244478B2 (enExample) |
| BR (1) | BR112020019710A2 (enExample) |
| CA (1) | CA3095086A1 (enExample) |
| CO (1) | CO2020013252A2 (enExample) |
| MX (1) | MX2020010144A (enExample) |
| TW (2) | TW202504926A (enExample) |
| WO (1) | WO2019186273A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| CN112513087B (zh) * | 2018-09-11 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 抗cd38抗体、其抗原结合片段及医药用途 |
| MA53920A (fr) * | 2018-10-17 | 2021-09-15 | Janssen Biotech Inc | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 |
| AU2020397170A1 (en) * | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
| BR112022023137A2 (pt) * | 2020-05-15 | 2023-02-07 | Takeda Pharmaceuticals Co | Administração de inibidor de enzima de ativação de sumo e anticorpos anti-cd38 |
| EP4376869A1 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| US20240400711A1 (en) * | 2021-09-23 | 2024-12-05 | Sound Biopharmaceuticals Co. Ltd. | Cd38 monoclonal antibody and application thereof |
| US20260217850A1 (en) * | 2022-12-21 | 2026-07-30 | Sound Biopharmaceuticals Co. Ltd. | Cd38 monoclonal antibody and use thereof |
| KR20250135226A (ko) | 2023-01-06 | 2025-09-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 자가면역 질환의 치료를 위한 항-cd38 항체 |
| WO2025193746A1 (en) | 2024-03-12 | 2025-09-18 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia |
| WO2025235919A1 (en) | 2024-05-09 | 2025-11-13 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| IT1320715B1 (it) | 2000-10-19 | 2003-12-10 | Cselt Centro Studi Lab Telecom | Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| EP1411851B1 (en) | 2001-08-03 | 2006-11-02 | Tyco Healthcare Group LP | Marker for use with a tissue marking apparatus |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| EP2551282A3 (en) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| MX373301B (es) | 2013-10-31 | 2020-04-24 | Sanofi Sa | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. |
| US10533057B2 (en) | 2015-05-13 | 2020-01-14 | Morphosys Ag | Treatment for multiple myeloma (MM) |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| MA45674A (fr) * | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
-
2019
- 2019-03-27 CA CA3095086A patent/CA3095086A1/en active Pending
- 2019-03-27 US US17/041,783 patent/US20210047427A1/en active Pending
- 2019-03-27 WO PCT/IB2019/000314 patent/WO2019186273A1/en not_active Ceased
- 2019-03-27 KR KR1020207030604A patent/KR20210002499A/ko not_active Ceased
- 2019-03-27 AU AU2019244478A patent/AU2019244478B2/en active Active
- 2019-03-27 BR BR112020019710-6A patent/BR112020019710A2/pt unknown
- 2019-03-27 KR KR1020257024758A patent/KR20250117714A/ko active Pending
- 2019-03-27 EP EP19726474.0A patent/EP3774915A1/en active Pending
- 2019-03-27 JP JP2020551797A patent/JP7526099B2/ja active Active
- 2019-03-27 CN CN201980032101.8A patent/CN112154156A/zh active Pending
- 2019-03-27 MX MX2020010144A patent/MX2020010144A/es unknown
- 2019-03-28 TW TW113121338A patent/TW202504926A/zh unknown
- 2019-03-28 TW TW108110990A patent/TWI847979B/zh active
-
2020
- 2020-10-22 CO CONC2020/0013252A patent/CO2020013252A2/es unknown
-
2023
- 2023-12-25 JP JP2023218600A patent/JP2024045121A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259859A patent/AU2025259859A1/en active Pending